Enrolling by invitationNo phase

Effects of GLP-1 obesity medicines on health and costs in working adults

Compares health and costs in insured adults with obesity, with and without these medicines.

Key facts

Who runs it: Indiana University
Where: Indianapolis, United StatesSee the site
Trial code: NCT07640139
Registry title: Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Status: Enrolling by invitation
People taking part: 125,000 people, planned
Started: 1 Jan 2026
Expected to end: 31 Dec 2029
Type of study: Observational, 2 groups
Treatments tested: Incretin-based therapies (GLP-1 and GLP-1/GIP)
Record updated: 10 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-64 living in Indiana who get health insurance through a taking-part employer and who qualify for an obesity medication prescription.

Age: 18 to 64 years
Sex: All sexes
Disease stage: BMI of 30 or more (obesity), or BMI of 25 or more (overweight) with at least one weight-related condition, such as high blood pressure, dyslipidemia, type 2 diabetes, obstructive sleep apnea or heart and blood vessel disease.
Earlier treatment: No earlier use of incretin-based obesity medications for weight loss and no earlier bariatric surgery. At least 6 months of insurance enrollment before joining.

Main reasons for not taking part

Cancer (except non-melanoma skin cancer), pancreatitis, eating disorders, HIV, unintentional weight loss or cirrhosis at the start
A condition for which obesity medications must not be used, such as medullary thyroid carcinoma or multiple endocrine neoplasia
Diabetes incretin medication claims (for example Mounjaro, Ozempic, Rybelsus, Victoza) without an obesity-medication claim
Earlier bariatric surgery
Earlier use of incretin-based obesity medications for weight loss

The registry criteria, word for word

Show all 12 criteriaShow less

Other criteria

The study cohort is limited to employees and adult dependents aged 18-64 who receive their health insurance coverage from self-insured Indiana employers that agree to participate in the study
To be included in the study, the individuals must:
Be an Indiana resident
Have health insurance benefits provided by participating employers (includes employees and dependents)
Be between the ages of 18 and 64
Meet the eligibility criteria for an obesity medication prescription:; BMI of ≥ 30 (obesity) or; BMI of ≥ 25 (overweight) and at least one body weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). If the prescribing eligibility criteria are updated in the future, we will update accordingly
Individuals must have at least 6 months of enrollment prior to study inclusion (i.e., prior to the index date), though we may use additional pre-treatment data if available; An individual who meets any of the following criteria will be excluded from participation in the cohort:
Has a condition associated with weight loss: a diagnosis of cancer (except for non-melanoma skin cancer), pancreatitis, eating disorders (e.g., anorexia nervosa and avoidant restrictive food intake disorder), HIV, unintentional weight loss, or cirrhosis at baseline
Has a condition for which obesity medications are contraindicated (for example, medullary thyroid carcinoma, multiple endocrine neoplasia, etc.)
Receipt of diabetes-indicated incretin-based medications. If an individual has a claim for a related incretin-based therapy diabetes medication (e.g., Mounjaro, Ozempic, Rybelsus, Victoza) without an obesity-medication claim during the study period, the individual will be excluded from analysis
Prior bariatric surgery
Evidence of prior use of incretin-based obesity medications for weight loss

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 64 years old?

Where in United States

Indiana UniversityIndianapolis, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are:

Read full original descriptionShow less

1. Is obesity medication usage is associated with reduced body mass index (BMI) and weight? 2. Is obesity medication usage is associated with reduced utilization of emergency department and inpatient care or obesity-related conditions over time? 3. Is obesity medication usage is associated with increased utilization of outpatient care over time? 4. Is obesity medication usage is associated with slower growth in direct medical costs over time? 5. Is obesity medication usage is associated with improvements in health measures? 6. Is obesity medication usage associated with reduced workplace costs?

Researchers will compare individuals who have prescriptions for obesity medications to those without to see if differences in health and costs of care exist.

The study uses existing medical and pharmacy claims data.

The 2 groups in the trial

Persistent use of incretin-based obesity medication
Persistent use is defined as continuous treatment with no gaps greater than 60 days between prescription fills. Discontinuation is defined as a gap exceeding 60 days following the expected end date of a prescription fill (based on days' supply). Exposure will be measured longitudinally from the index date until discontinuation or censoring. Days of supply will be calculated from pharmacy claims, and we will account for stockpiling by allowing early refills to extend coverage forward in time. If days' supply is missing, it will be imputed using prescribing guidelines or external data sources.
Treatment: Incretin-based therapies (GLP-1 and GLP-1/GIP)
No documented receipt of incretin-based obesity medication during observation period
Working-age adults (age 18 to 64) insured by participating Indiana-based employers that do not use any incretin-based obesity medication for weight loss. Identified by no claim for obesity medications (accounting for days supply and available refills).